UBS AG Post Stabilisation Notice - Nidda Healthcare FRN
November 15 2024 - 11:39AM
RNS Regulatory News
RNS Number : 5097M
UBS AG
15 November 2024
15th November 2024
Not for
distribution, directly or indirectly, in or into the United States
or any jurisdiction in which such distribution would be
unlawful.
Nidda Healthcare
Holding GmbH
Post-Stabilisation Notice
UBS Investment Bank (contact: Debt Syndicate;
telephone: +44 20 7567 2477 hereby gives notice that no
stabilisation (within the meaning of the rules of the Financial
Conduct Authority was undertaken by the Stabilising Manager named
below in relation to the offer of the following
securities.
|
Issuer:
|
Nidda Healthcare
Holding GmbH
|
|
Guarantor (if any):
|
German Holdco, EG SA
(formerly, Eurogenerics SA), Internis Pharmaceuticals Limited,
Thornton & Ross Limited, STADA, Clonmel Healthcare Limited,
Centrafarm B.V., Crosspharma Limited, Britannia Pharmaceuticals
Limited and Natures Aid Ltd, collectively
|
|
Aggregate nominal amount:
|
EUR 600,000,000
|
|
Description:
|
Senior Secured Floating Rate Notes
due 2030
|
|
Stabilising Manager(s)
|
UBS AG London Branch
|
This announcement is for information purposes
only and does not constitute an invitation or offer to underwrite,
subscribe for or otherwise acquire or dispose of any securities of
the Issuer in any jurisdiction.
This announcement is not an offer of securities
for sale into the United States. The securities referred to above
have not been, and will not be, registered under the United States
Securities Act of 1933 and may not be offered or sold in the United
States absent registration or an exemption from registration.
There has not been and will not be a public offer of the securities
in the United States.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
STAFLFVDLRLELIS
Ubs 43 (LSE:17WI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Ubs 43 (LSE:17WI)
Historical Stock Chart
From Dec 2023 to Dec 2024
